Fintel reports that on January 30, 2026, Needham upgraded their outlook for Globus Medical (NYSE:GMED) from Hold to Buy.
Analyst Price Forecast Suggests 17.49% Upside
As of January 14, 2026, the average one-year price target for Globus Medical is $106.00/share. The forecasts range from a low of $78.78 to a high of $123.90. The average price target represents an increase of 17.49% from its latest reported closing price of $90.22 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Globus Medical is 1,303MM, a decrease of 52.96%. The projected annual non-GAAP EPS is 3.43.
What is the Fund Sentiment?
There are 925 funds or institutions reporting positions in Globus Medical. This is an decrease of 73 owner(s) or 7.31% in the last quarter. Average portfolio weight of all funds dedicated to GMED is 0.30%, an increase of 4.45%. Total shares owned by institutions decreased in the last three months by 2.66% to 142,789K shares. 
The put/call ratio of GMED is 0.64, indicating a bullish outlook.
What are Other Shareholders Doing?
Janus Henderson Group holds 7,553K shares representing 6.78% ownership of the company. In its prior filing, the firm reported owning 8,207K shares , representing a decrease of 8.66%. The firm decreased its portfolio allocation in GMED by 16.82% over the last quarter.
Jpmorgan Chase holds 3,682K shares representing 3.30% ownership of the company. In its prior filing, the firm reported owning 3,341K shares , representing an increase of 9.27%. The firm decreased its portfolio allocation in GMED by 2.02% over the last quarter.
IJH - iShares Core S&P Mid-Cap ETF holds 3,680K shares representing 3.30% ownership of the company. In its prior filing, the firm reported owning 3,708K shares , representing a decrease of 0.76%. The firm decreased its portfolio allocation in GMED by 24.56% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,628K shares representing 3.26% ownership of the company. In its prior filing, the firm reported owning 3,619K shares , representing an increase of 0.23%. The firm decreased its portfolio allocation in GMED by 27.90% over the last quarter.
Sculptor Capital holds 3,500K shares representing 3.14% ownership of the company. In its prior filing, the firm reported owning 2,761K shares , representing an increase of 21.12%. The firm increased its portfolio allocation in GMED by 2.73% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
